title: Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors.
abstract: Lentivirus-based gene transfer has the potential to efficiently deliver DNA-based therapies into non-dividing epithelial cells of the airway for the treatment of lung diseases such as cystic fibrosis. However, significant barriers both to lung-specific gene transfer and to production of lentivirus vectors must be overcome before these vectors can be routinely used for applications to the lung. In this study, we investigated whether the ability to produce lentiviral vectors pseudotyped with fowl plague virus hemagglutinin (HA) could be improved by co-expression of influenza virus M2 in vector-producing cells. We found that M2 expression led to a 10-30-fold increase in production of HA-pseudotyped lentivirus vectors based upon equine infectious anemia virus (EIAV) or human immunodeficiency virus type 1 (HIV-1). Experiments using the M2 inhibitor amantadine and a drug-resistant mutant of M2 established that the ion channel activity of M2 was important for M2-dependent augmentation of vector production. Furthermore, the neuraminidase activity necessary for particle release from producer cells could also be incorporated into producer cells by co-expression of influenza NA cDNA. Lentiviral vectors pseudotyped with influenza envelope proteins were able to efficiently transduce via the apical membrane of polarized mouse tracheal cultures in vitro as well as mouse tracheal epithelia in vivo.
authors.affiliation: Department of Medicine, Cystic Fibrosis/Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, 27599, USA.
authors.forename: T
authors.initials: T
authors.lastname: McKay
authors.forename: M
authors.initials: M
authors.lastname: Patel
authors.forename: R J
authors.initials: RJ
authors.lastname: Pickles
authors.forename: L G
authors.initials: LG
authors.lastname: Johnson
authors.forename: J C
authors.initials: JC
authors.lastname: Olsen
mesh_terms: D000818:Animals; D005455:Fluorescent Antibody Technique; D005818:Genetic Engineering; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics*; D005838:Genotype; D015497:HIV-1 / Q000235:genetics; D006389:Hemagglutinins, Viral / Q000235:genetics; D006801:Humans; D004860:Infectious Anemia Virus, Equine / Q000235:genetics; D009980:Influenza A virus / Q000235:genetics; D016086:Lentivirus / Q000235:genetics*; D008171:Lung Diseases / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D014132:Trachea / Q000821:virology; D014161:Transduction, Genetic / Q000379:methods*; D014763:Viral Matrix Proteins / Q000235:genetics*; D000086082:Viroporin Proteins
chemical_list: D006389:Hemagglutinins, Viral; D014763:Viral Matrix Proteins; C488937:M2 protein, Influenza A virus; D000086082:Viroporin Proteins